BTIG Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $11

Benzinga · 2d ago
BTIG analyst Jeet Mukherjee initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $11.